BENLYSTA Powder for Concentrate for Solution for Infusion
Belimumab
400 mg
AMERSHAM HEALTH
| Pack size | 1 Vial |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 1509.10 AED |
Indications
BENLYSTA Powder for Concentrate for Solution for Infusion is used for:
Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Belimumab :
Mechanism of Action
Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Note
BENLYSTA 400 mg Powder for Concentrate for Solution for Infusion manufactured by AMERSHAM HEALTH. Its generic name is Belimumab. BENLYSTA is availble in Saudi Arabia.
Farmaco SA drug index information on BENLYSTA Powder for Concentrate for Solution for Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.